A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis
Public ClinicalTrials.gov record NCT03222609. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Open-Label Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Subjects With Myelofibrosis (REFINE)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 2 open-label, multicenter study evaluating tolerability and efficacy of navitoclax alone or when added to ruxolitinib in participants with myelofibrosis.
Study identification
- NCT ID
- NCT03222609
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 191 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2017 (Actual)
- Primary completion
- Mar 28, 2022 (Actual)
- Completion
- Jan 29, 2025 (Actual)
- Last update posted
- Jan 20, 2026
2017 – 2025
United States locations
- U.S. sites
- 33
- U.S. states
- 19
- U.S. cities
- 30
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UAB Comprehensive Cancer Cente /ID# 165464 | Birmingham | Alabama | 35217 | — |
| TOI Clinical Research /ID# 222546 | Cerritos | California | 90703-2679 | — |
| City of Hope /ID# 221395 | Duarte | California | 91010 | — |
| Moores Cancer Center at UC San Diego /ID# 164084 | La Jolla | California | 92093 | — |
| Long Beach Memorial Medical Ct /ID# 230148 | Long Beach | California | 90806-1701 | — |
| University of Southern California /ID# 164095 | Los Angeles | California | 90033 | — |
| Colorado Blood Cancer Institute /ID# 224250 | Denver | Colorado | 80218 | — |
| Baptist MD Anderson Cancer Center - Jacksonville /ID# 222548 | Jacksonville | Florida | 32207-8432 | — |
| Mayo Clinic /ID# 164201 | Jacksonville | Florida | 32224 | — |
| Moffitt Cancer Center /ID# 164082 | Tampa | Florida | 33612-9416 | — |
| University of Chicago Medicine /ID# 164115 | Chicago | Illinois | 60637-1426 | — |
| Mid Illinois Hematology & Oncology Associates, Ltd /ID# 230536 | Normal | Illinois | 61761 | — |
| Indiana Blood & Marrow Transpl /ID# 165075 | Indianapolis | Indiana | 46237 | — |
| Duplicate_American Oncology Partners of Maryland, PA /ID# 231299 | Bethesda | Maryland | 20817 | — |
| Dana-Farber Cancer Institute /ID# 162675 | Boston | Massachusetts | 02215 | — |
| University of Massachusetts - Worcester /ID# 222547 | Worcester | Massachusetts | 01655 | — |
| Henry Ford Hospital /ID# 162682 | Detroit | Michigan | 48202 | — |
| Ascension Providence Southfield Cancer Center /ID# 223876 | Southfield | Michigan | 48075-3707 | — |
| MidAmerica Division, Inc. /ID# 222058 | Kansas City | Missouri | 64132 | — |
| Weill Cornell Medical College /ID# 162679 | New York | New York | 10065 | — |
| The Ohio State University /ID# 217402 | Columbus | Ohio | 43210-1280 | — |
| Bend Memorial Clinic /ID# 224184 | Bend | Oregon | 97701 | — |
| West Penn Hospital /ID# 222618 | Pittsburgh | Pennsylvania | 15224-1722 | — |
| Duplicate_Medical University of South Carolina /ID# 222597 | Charleston | South Carolina | 29425 | — |
| Prairie Lakes Healthcare System /ID# 224358 | Watertown | South Dakota | 57201 | — |
| Tennessee Oncology-Nashville Centennial /ID# 221410 | Nashville | Tennessee | 37203-1632 | — |
| Texas Oncology - West Texas /ID# 224784 | Abilene | Texas | 79606 | — |
| Texas Oncology- Baylor Charles A. Sammons Cancer Center /ID# 225159 | Dallas | Texas | 75246-2003 | — |
| Oncology Consultants /ID# 230930 | Houston | Texas | 77030-3306 | — |
| MD Anderson Cancer Center at Texas Medical Center /ID# 162683 | Houston | Texas | 77030-4000 | — |
| University of Texas Health San Antonio MD Anderson Cancer Center /ID# 164094 | San Antonio | Texas | 78229 | — |
| Utah Cancer Specialists Salt Lake Clinic /ID# 222806 | Salt Lake City | Utah | 84106 | — |
| University of Utah /ID# 164116 | Salt Lake City | Utah | 84112-5500 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 58 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03222609, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 20, 2026 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03222609 live on ClinicalTrials.gov.